EGAS00001000285-sc-20130612 - samples

We recently used the Agilent SureSelect platform to re-sequence a set of genes known to be
mutated in human AML. The results from 10 AML DNA samples were very satisfactory, but
the effort required was significant.
Thus, we decided to re-sequence the same genes using the Haloplax system for target
enrichment in 48 AML samples. We planned to do this using MiSeq and have data from a
pilot of 3 samples. The data is promising but coverage appears pathcy so far.
However, in order to get a better understanding of the data we will need deeper sequencing. We
will need two lanes of HiSeq to get the same degree coverage as Sureselect.

his data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/EGA dataset EGAD00001000603

我们近期采用安捷伦SureSelect（Agilent SureSelect）平台，对一组已知在人类急性髓系白血病（Acute Myeloid Leukemia, AML）中发生突变的基因开展重测序。针对10份AML患者DNA样本的测序结果十分理想，但所需实验工作量极大。
因此，我们决定采用Haloplax靶向富集系统，对48份AML样本中的同一组基因进行重测序。原计划使用MiSeq测序仪（MiSeq）完成该实验，并已获得3份样本的预实验数据。目前的数据颇具潜力，但测序覆盖度至今仍存在明显不均的问题。
然而，为了更全面地解析这批数据，我们需要开展更深层次的测序：若要达到与SureSelect平台相当的覆盖度，需使用HiSeq测序仪（HiSeq）的两个测序泳道。
本数据集属于预公开发布的数据范畴。若需了解威康桑格研究所（Wellcome Trust Sanger Institute）共享的预公开数据的规范使用方法（包括相关出版暂缓条款的详细说明），请访问：http://www.sanger.ac.uk/datasharing/ 对应的EGA数据集EGAD00001000603。